Dr. Vishal Gulati is a specialist health and life sciences investor driving a successful mission to help scientists and technical founders bring their innovations to market. The combination of training as a clinician scientist at University of Oxford and Imperial College followed by a career in Venture Capital gives him a rare and unique perspective on the journey of scientific discoveries into commercially successful products.

Vishal has served on the boards of over fifteen public and private life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by US based Perkin Elmer) to the world's most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European AI drug discovery companies such as Arctoris, Turbine, Relation Therapeutics and AI Vivo. His portfolio of over 30 investments makes him one of the most active investors in this space.

During his educational career Vishal received two ICMR Fellowships, UNESCO MCBN Fellowship and the Rhodes Scholarship. Leading educational and scientific institutions have recognised Vishal’s leadership by appointing him to their panels; Vishal chairs the investment committee of Cancer Research UK), and similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal has advised the UK Government's Office of Life Sciences on future life sciences strategy and through his advisory board position at Reuben College, the newest of the Oxford University Colleges, he is helping to create unique opportunities for post-graduate students to explore life sciences in the context of emerging technologies such as artificial intelligence.